Anti-angiogenic-specific adverse events in patients with non-small cell lung cancer treated with nintedanib and docetaxel

作者:Reck Martin*; Mellemgaard Anders; von Pawel Joachim; Gottfried Maya; Bondarenko Igor; Cheng Ying; Zarogoulidis Kostas; Luft Alexander; Bennouna Jaafar; Barrueco Jose; Aboshady Hesham; Hocke Julia; Kaiser Rolf; Douillard Jean Yves
来源:Lung Cancer, 2015, 90(2): 267-273.
DOI:10.1016/j.lungcan.2015.08.003

摘要

Objectives: LUME-Lung 1 was a randomized, placebo-controlled, Phase III trial investigating nintedanib + docetaxel versus placebo + docetaxel in patients with advanced NSCLC progressing after first-line chemotherapy. Progression-free survival was significantly improved with nintedanib + docetaxel in the overall population and overall survival was significantly improved in the pre-specified analysis of patients with adenocarcinoma. We evaluated the frequency of characteristic adverse events (AEs) commonly seen with existing anti-angiogenic agents. Materials and methods: The incidence and intensity of AEs were evaluated in all patients who received at least one dose of study medication (N = 1307) and for the two main histologies: adenocarcinoma (n = 653) and squamous cell carcinoma (SCC; n = 553). AEs of special interest were analyzed by category, preferred term, and worst CTCAE grade and included perforation, hypertension, bleeding, thromboembolic events, and skin disorders. Results and conclusion: The incidence of patients with all-grade gastrointestinal (GI) perforations was low and balanced between arms (0.5% in both) and across histologies; the incidence of non-GI perforations was 1.2% with nintedanib + docetaxel versus 0.2% with placebo + docetaxel. The incidence of some events was higher with nintedanib + docetaxel versus placebo + docetaxel; hypertension (3.5% vs 0.9%), rash (11.0% vs 8.1%), and cutaneous adverse reactions (13.0% vs 10.7%). Rash and cutaneous adverse reactions were predominantly Grade 1-2 with both treatments. The incidence of all-grade bleeding was also slightly higher in nintedanib + docetaxel-treated patients (14.1% vs 11.6%) driven by between-treatment differences in the SCC subpopulation; most events were Grade 1-2. The proportion of patients with a thromboembolic event was low and comparable between arms for all grades (5.1% vs 4.6%) and Grade >= 3 (2.1% vs 3.1%). Safety evaluation of the LUME-Lung 1 study showed that the frequency of AEs commonly associated with other anti-angiogenic agents was lower with nintedanib + docetaxel. Survival benefits from addition of nintedanib to docetaxel in patients with adenocarcinoma after first-line therapy can be achieved alongside a manageable safety profile.

  • 出版日期2015-11
  • 单位吉林省肿瘤医院